Browsing Tag
Arcus Biosciences
3 posts
Is Arcus Biosciences (RCUS) the dark horse of cancer immunotherapy after 26.7-month survival data?
Arcus stock jumped after its domvanalimab-zimberelimab combo showed 26.7-month survival in gastric cancer. Find out what this means for its TIGIT pipeline.
Gilead and Arcus announce significant advancement in metastatic colorectal cancer treatment with etrumadenant plus zimberelimab regimen
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) have released promising new data from their…
Gilead Sciences invests $320m in Arcus Biosciences to accelerate cancer treatment innovations
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) have announced a significant amendment to their…